Cytek Biosciences (CTKB) Current Deferred Revenue (2020 - 2026)

Cytek Biosciences has reported Current Deferred Revenue for 7 years, with the latest figure at $30.0 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue rose 8.4% year-over-year to $30.0 million; the trailing twelve-month figure through Mar 2026 stood at $30.0 million (up 8.4% YoY), and the FY2025 full-year result was $28.5 million, up 11.82% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $30.0 million, up from $28.5 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $30.0 million in Q1 2026, with the low at $10.0 million in Q2 2022.
• Historically, Current Deferred Revenue has averaged $22.6 million across 5 years, with a median of $23.5 million in 2022.
• The largest YoY upside for Current Deferred Revenue was 114.03% in 2022 against a maximum downside of 48.37% in 2022.
• Cytek Biosciences' Current Deferred Revenue stood at $13.0 million in 2022, then soared by 74.77% to $22.7 million in 2023, then advanced by 12.32% to $25.5 million in 2024, then rose by 11.82% to $28.5 million in 2025, then increased by 5.36% to $30.0 million in 2026.
• The last three Current Deferred Revenue figures came in at $30.0 million (Q1 2026), $28.5 million (Q4 2025), and $28.7 million (Q3 2025), per Business Quant data.